SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AstraZeneca PLC and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
LOS ANGELES, Jan. 29, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against AstraZeneca PLC ("AstraZeneca" or "the Company") (NASDAQ: AZN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between May 21, 2020 and November 20, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before March 27, 2021.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. AstraZeneca's initial clinical trials for its COVID-19 vaccine, AZD1222, suffered from manufacturing errors. The validity and import of the Company's clinical trials for AZD1222 were damaged by a patchwork of differentiated patient subgroups, each with subtly different treatments. Some trial participants did not receive a second dose of the vaccine candidate at the designated time, in some cases receiving them weeks later. The Company failed to include a substantial sample of patients aged over 55, despite this population being a high priority for vaccination. The Company's clinical trials were generally damaged by widespread design errors and flawed execution. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about AstraZeneca, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
SOURCE The Schall Law Firm
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article